LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Home・Aktien・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

8.36 -0.71

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

8.24

Max

8.42

Schlüsselkennzahlen
By Trading Economics
Einkommen	11M -20M
Verkäufe	5.9M 40M
EPS	-0.19
Gewinnspanne	-49.569
Angestellte	184
EBITDA	16M -19M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+184.09% upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	138M 887M
Vorheriger Eröffnungskurs	9.07
Vorheriger Schlusskurs	8.36

Nachrichtenstimmung

By Acuity

50%

158 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

6.26 / 7.47 Unterstützung & Widerstand

Day One Biopharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

14. Dez. 2025, 22:53 UTC

Akquisitionen, Fusionen, Übernahmen

Fortescue to Take Full Control of US$101 Million Copper Miner Alta

13. Dez. 2025, 00:04 UTC

Akquisitionen, Fusionen, Übernahmen

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

14. Dez. 2025, 23:46 UTC

Market Talk

Gold Edges Higher Amid Some Tailwinds -- Market Talk

14. Dez. 2025, 23:36 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

14. Dez. 2025, 22:38 UTC

Akquisitionen, Fusionen, Übernahmen

Fortescue to Take Full Control of US$101M Copper Miner Alta

14. Dez. 2025, 22:02 UTC

Akquisitionen, Fusionen, Übernahmen

Fortescue: Transaction Is Consistent With Critical Minerals Strategy

14. Dez. 2025, 22:01 UTC

Akquisitionen, Fusionen, Übernahmen

Fortescue: Alta Owns the Canariaco Project in Northern Peru

14. Dez. 2025, 22:01 UTC

Akquisitionen, Fusionen, Übernahmen

Fortescue: Alta Directors Unanimously Recommend Proposal, Will Vote in Favor

14. Dez. 2025, 22:00 UTC

Akquisitionen, Fusionen, Übernahmen

Fortescue: Agreement Implies Total Equity Value of C$139 Million

14. Dez. 2025, 22:00 UTC

Akquisitionen, Fusionen, Übernahmen

Fortescue to Pay C$1.40/Share for Securities It Does Not Already Own

14. Dez. 2025, 21:59 UTC

Akquisitionen, Fusionen, Übernahmen

Fortescue to Acquire Remaining 64% of Alta Copper

14. Dez. 2025, 17:00 UTC

Ergebnisse

Tonka Trucks Gambled on Keeping Production in China and Survived -- Barely -- WSJ

14. Dez. 2025, 08:30 UTC

Akquisitionen, Fusionen, Übernahmen

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

13. Dez. 2025, 16:48 UTC

Akquisitionen, Fusionen, Übernahmen

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13. Dez. 2025, 08:00 UTC

Akquisitionen, Fusionen, Übernahmen

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13. Dez. 2025, 07:00 UTC

Akquisitionen, Fusionen, Übernahmen

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

13. Dez. 2025, 00:24 UTC

Akquisitionen, Fusionen, Übernahmen

Want a Piece Of SpaceX? -- Barrons.com

12. Dez. 2025, 23:49 UTC

Akquisitionen, Fusionen, Übernahmen

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12. Dez. 2025, 22:52 UTC

Market Talk

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12. Dez. 2025, 22:32 UTC

Ergebnisse

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12. Dez. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. Dez. 2025, 20:45 UTC

Ergebnisse

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12. Dez. 2025, 20:41 UTC

Market Talk

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12. Dez. 2025, 20:20 UTC

Market Talk

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12. Dez. 2025, 19:23 UTC

Ergebnisse

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12. Dez. 2025, 18:35 UTC

Akquisitionen, Fusionen, Übernahmen

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12. Dez. 2025, 18:33 UTC

Akquisitionen, Fusionen, Übernahmen

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12. Dez. 2025, 18:31 UTC

Market Talk

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12. Dez. 2025, 17:49 UTC

Ergebnisse

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12. Dez. 2025, 17:34 UTC

Akquisitionen, Fusionen, Übernahmen

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

Peer-Vergleich

Kursveränderung

Day One Biopharmaceuticals Inc Prognose

Kursziel

By TipRanks

184.09% Vorteil

12-Monats-Prognose

Durchschnitt 23.75 USD 184.09%

Hoch 34 USD

Tief 16 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Day One Biopharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

9 ratings

Buy

Halten

Sell

Basierend auf 9 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Day One Biopharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

6.26 / 7.47Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Stimmung

By Acuity

158 / 374 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.